Avène relies on AI to enhance its clinical studies

Pierre Fabre Laboratories is taking a significant step forward in the application of artificial intelligence in dermo-cosmetics. In 2026, Avène will launch a comparative clinical study of Cleanance Comedomed+, a skincare product for acne-prone skin in the maintenance phase following isotretinoin treatment. The trial will involve two groups (active and placebo), and will feature a major innovation: the artificial increase in sample size through the generation of synthetic data, in collaboration with Toulouse-based HealthTech company BotDesign. Up to 500 additional virtual patients can be included to strengthen the statistical power of the results.

The method, presented at conferences and currently being published in scientific journals, is heralded as a first in dermo-cosmetics. Results are expected in December 2026.